By Fineline Cube D3 Bio, a China-based biotechnology company, presented updated Phase I/II clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated elisrasib as monotherapy and in combination with pembrolizumab in patients with KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC), with the first-line combination cohort demonstrating unprecedented efficacy: an 81.3% objective response rate (ORR) and 97.9% disease control rate (DCR) among 48 efficacy-evaluable patients. The regimen also showed 74.6% 6-month progression-free survival (PFS) and 53.7% 12-month PFS rates.
Clinical Trial Results
| Parameter | Result |
|---|---|
| Patient Population | First-line KRAS G12C-mutant NSCLC (52 patients enrolled) |
| Regimen | Elisrasib 600 mg once daily + pembrolizumab 200 mg Q3W |
| Efficacy-Evaluable Patients | 48 |
| Objective Response Rate (ORR) | 81.3% |
| Disease Control Rate (DCR) | 97.9% |
| 6-Month PFS Rate | 74.6% |
| 12-Month PFS Rate | 53.7% |
| Safety Profile | Consistent with known profiles of individual agents |
Drug Profile & Mechanism of Action
- Molecule: Elisrasib (D3S-001) – next-generation KRAS G12C inhibitor
- Target: KRAS G12C mutation, present in approximately 13% of NSCLC cases
- Combination Strategy: Synergistic approach combining KRAS pathway inhibition with PD-1 immune checkpoint blockade
- Dosing: Oral administration (600 mg once daily) with convenient weekly pembrolizumab dosing
- Development Stage: Phase I/II clinical trial with focus on first-line treatment setting
Strategic Clinical Implications
The ASCO 2026 data positions elisrasib as a potential practice-changing therapy in first-line KRAS G12C-mutant NSCLC:
- Unprecedented ORR: 81.3% response rate significantly exceeds historical benchmarks for first-line NSCLC therapies
- High Disease Control: 97.9% DCR indicates near-universal disease stabilization or improvement
- Durable Responses: 53.7% 12-month PFS rate suggests meaningful long-term benefit
- First-Line Focus: Addresses the largest treatment-naïve patient population with optimal therapeutic window
- Combination Rationale: KRAS inhibition may enhance tumor immunogenicity, creating synergy with PD-1 blockade
“This remarkable efficacy data establishes elisrasib plus pembrolizumab as a highly promising first-line treatment option for KRAS G12C-mutant NSCLC,” said Dr. Li Ming, Chief Executive Officer of D3 Bio. “The 81% response rate and excellent disease control demonstrate the power of combining targeted therapy with immunotherapy in this molecularly defined patient population.”
Competitive Landscape & Market Opportunity
The results position D3 Bio to challenge established players in the KRAS G12C inhibitor space:
- Market Context: KRAS G12C represents one of the most common oncogenic drivers in NSCLC with significant unmet need
- Competitive Differentiation: First-line data with 81% ORR substantially exceeds historical response rates for single-agent KRAS inhibitors (~40–45% in second-line)
- Addressable Population: Approximately 15,000–20,000 newly diagnosed KRAS G12C-mutant NSCLC patients annually in the U.S.
- Global Potential: Data supports rapid international regulatory filings and partnership opportunities
Industry analysts view the 81% ORR in first-line setting as potentially transformative, with peak annual sales estimates of $2–3 billion if Phase III confirms these results, given the substantial addressable market and premium pricing potential for breakthrough first-line therapies.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities for elisrasib. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech